Medical/Pharmaceuticals
Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma
SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- Asieris Pharmaceuticals today released its 2026 Semi-Annual Report, showing comprehensive progress across all business segments. With the gradual realization of commercial launch and international expansion for its core products, the company is accelerating...
2026-08-28 19:31
2944
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the ...
2026-08-28 19:30
3228
InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation
NANJING, China, Aug. 28, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selectiv...
2026-08-28 19:00
2371
Tigermed Announces 2026 Interim Results
HANGZHOU, China, Aug. 28, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its 2026 interim results (the "Reporting Period"). ...
2026-08-28 17:56
3680
DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform
* Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and global commercialization * DUPAC, one of the DualityBio's four proprietary ADC technology platforms, comprises...
2026-08-28 12:20
2359
Singclean 2nd Leaders Summit Charts New Course in Global Aesthetics
SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- Hosted within the IMCAS China Conference venue at W Shanghai - The Bund, Singclean 2nd International Medical Aesthetic Leaders Summit themed "Global Vision, Embark on a New Chapter" came to a successful conclusion. 2026 IMCAS China Singclean Highlight Vid...
2026-08-28 11:00
2658
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further advanced its global immuno-oncology (IO) 2.0 strategy, progressively built its IO2...
2026-08-28 10:44
6291
NECA Expands Telehealth Care with New Counselling and Dietitian Support
NeuroEndocrine Cancer Australia strengthens free specialist support for patients, carers, and families affected by neuroendocrine cancer. SYDNEY, Aug. 28, 2026 /PRNewswire/ -- NeuroEndocrine Cancer Australia (NECA) has expanded its national telehealth service to include dedicated counselling and...
2026-08-28 07:00
2372
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
INCHEON, South Korea, Aug. 27, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in the company's three-dimensional, long-term growth strategy across capacity, portfolio, and geogr...
2026-08-28 06:58
3518
Kazia Therapeutics Limited Announces Proposed Public Offering
SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that...
2026-08-28 05:14
3809
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
Durable Complete Metabolic Response Ongoing Since November 2025 All Evaluable Patients Demonstrated Reductions in Metastasis-Associated CTC Clusters and Terminally Exhausted T cells, With Median Reductions of 83% and 51% Respectively No Treatment-Related Serious Adverse Events Observed SYDNEY, ...
2026-08-28 04:01
4286
Global genomics and multi-omics leader Novogene to establish its first Australian laboratory at Cabrini Health, accelerating access to precision cancer care
MELBOURNE, Australia, Aug. 28, 2026 /PRNewswire/ -- Global multi-omics leader Novogene is establishing its first Australian laboratory at Cabrini Health, bringing advanced genomic capabilities closer to Australian patients and researchers, reducing the wait for genomic test results that can infor...
2026-08-28 04:00
4868
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient...
2026-08-27 22:15
6344
Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced ...
2026-08-27 22:09
2673
Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today an...
2026-08-27 22:04
5471
ZEISS debuts DORC EVA NEXUS for cataract surgery at ESCRS
Now spanning ZEISS Retina and Cataract Workflows, the EVA NEXUS™ ophthalmic
surgical system from ZEISS comes in a cataract-only configuration, bringing a
tailored approach to different surgical needs.
JENA, Germany, Aug. 27, 2026 /PRNewswire/ -- | Carl Zeiss Meditec AG
2026-08-27 21:03
1843
Neurophet Supplies 'Neurophet AQUA' and 'Neurophet AQUA AD Plus' to Elevate Clinic in the U.S., Expanding Its Presence in the U.S. Brain Disorders Market
* Provides solutions for analyzing brain atrophy and white matter hyperintensities, as well as monitoring side effects associated with Alzheimer's disease treatments * Secures a key reference site at a U.S. medical institution specializing in neurological disorders, accelerating product adopt...
2026-08-27 21:00
3049
Neopharma Technologies Achieves ISO/IEC 42001:2023 AI Management System Certification for NEOVAULT® Global Diagnostics Platform
Certification strengthens the governance framework behind NEOVAULT® as Neopharma expands from Fit-for-Duty into broader human health diagnostics NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Neopharma Technologies Ltd ("Neopharma") today announced that it has achieved ISO/IEC 42001:2023 certification ...
2026-08-27 20:20
1891
Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion
Highlights: * Total revenue reached RMB86.96 billion, and profit attributable to owners of the parent reached RMB1.72 billion, representing a year-on-year increase of 160.3%; * Operational quality of core industries steadily improved, with industrial operation profit reaching RMB3.69 billion...
2026-08-27 19:27
3852
AsiaPay Partners with Generika Drugstore to Launch a Convenient and Secure Digital Payment Solution, Enhancing Customer Payment Experience in The Philippines
MANILA, Philippines, Aug. 27, 2026 /PRNewswire/ -- AsiaPay, a leading digital payment service provider and technology company in Asia, has partnered with Generika Drugstore, the country's premier generic pharma retail chain and part of AC Health, the healthcare arm of the Ayala Group, to signific...
2026-08-27 17:31
3153
Week's Top Stories
Most Reposted
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 294 media titles]
2026-09-24 10:30
Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 276 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 276 media titles]
2026-09-29 09:00
Nuix Recognised as a RiskTech100® 2027 Disruptor by Chartis Research
[Picked up by 274 media titles]
2026-09-25 08:30Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
13883
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
12600
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
11636
